Loading data...
Loading data...
Compare up to 4 stocks side by side, across all 7 of StockIQ's scoring categories.
| Category | DXCM Dexcom | ABT Abbott Laboratories |
|---|---|---|
| Price | $89.35 +1.6% | $102.61 +0.4% |
| StockIQ Score | 64C+ Moderate Risk: Medium | 51C- Moderate Risk: Medium |
| Technical | 72B | 19F |
| Fundamental | 79B+ | 72B |
| Growth | 79B+ | 45D+ |
| Fair Value | 33F | 38F |
| News | 56C | 100A+ |
| Quality | 58C | 63C+ |
| Risk | 48D+ | 54C- |
Scores are based on real financial data only and do not constitute investment advice. How the score is calculated
Dexcom outperforms Abbott in growth and fundamentals, with scores of 79 compared to 45 and 72 respectively. Its valuation score is slightly lower at 33 versus Abbott’s 38, but Dexcom’s technical score (60) still beats Abbott’s (50). Both share a "MODERATE" rating, but Dexcom’s higher growth and fundamentals make it stronger in those areas.